Schering Aktiengesellschaft

Bayer Intellectual Property Gmbh

Bayer Schering Pharma Ag

Bayer Pharma Aktiengesellschaft

Shering Ag

Schering Akitengesellschaft

Deutsches Krebsforschungszentrum Stiftung Des Offentlichen Rechts

Wolfgang Schwede

Ulrich Klar

Andrea Rotgeri

Wilhelm Bone

Arwed Cleve

Werner Skuballa

Bernd Buchmann

Martin Schneider

Gunter Neef

Eckhard Ottow

Karl-Heinrich Fritzemeier

Kristof Chwalisz

Wolfgang Halfbrodt

Hartmut Rehwinkel

Katja Zimmermann

Joachim Kuhnke

Duy Nguyen

Sven Ring

Krzysztof Chwalisz

Roland Neuhaus

Marcus Bauser

Rosemarie Lichtner

Sonja Anlauf

Jens Hoffmann

Olaf Panknin

Walter Elger

Hans Briem

Knut Eis

Karl-Heinz Thierauch

Georg Kettschau

Gerhard Sauer

Alexander Hillisch

Benjamin Bader

Norbert Schmees

Marcus Koppitz

Ulrich Bothe

Ursula Mönning

Carsten Möller

Ulrike Fuhrmann

Rolf Krattenmacher

Holger Heb-Stumpp

Hans-Peter Muhn

Holger Siebeneicher

Stefan Kaulfuss

Dieter Zopf

Michael Schirner

Klaus Schollkopf

Stuart Ince

Olaf Prien

Antonius Ter Laak

Hermann Kuenzer

Christoph Huwe

Judith Guenther

Paul Matthew Blaney

Ingo Hartung

Christa Hegele-Hartung

Jens Nagel

Ursula Krenz

Nico Bräuer

Peter Esperling

Ursula Moenning

Werner Boidol

Horst Irlbacher

Anne-Marie Godinho-Coelho

Roman Hillig

Uwe Kollenkirchen

Henrik Dahllöf

Manfred Husemann

Horst Michna

Andreas Von Deimling

Martina Schaefer

Michaele Peters

Hermann Künzer

Anja Schmidt

Carsten Moeller

Arndt Schmitz

Antonius M Laak Ter

Dominic E A Brittain

Stefan Pusch

Antonius M Ter Laak

The present invention relates to benzimidazol-2-amines of general formula (I), in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients.

Benzimidazol-2-amines as mIDH1 inhibitors

The present invention relates to substituted Pyridyl-cycloalkyl-carboxylic acids of general formula (I), to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular in mammals, such as diseases associated with pains, or for the treatment or prophylaxis of pain syndromes (acute and chronic), inflammatory-induced pain, pelvic pain, cancer-associated pain, endometriosis-associated pain as well as endometriosis and adenomyosis as such, cancer as such, and proliferative diseases as such like endometriosis. 

Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and medical uses thereof

The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of Formula I with progesterone antagonizing action and method of production thereof, use thereof for the treatment and/or prophylaxis of diseases and use thereof for the production of medicinal products for the treatment and/or prophylaxis of diseases, in particular of fibroids of the uterus (myomas, uterine leiomyoma), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause or for fertility control and emergency contraception.

17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives, method of production thereof and use thereof for the treatment of diseases

The present invention relates to benzimidazol-2-amines of general formula (I), in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

The present invention relates to benzimidazol-2-amines of general formula (I): in which R, R, R, R, R, R, R, R, R, R, Rand Rare as defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of neoplasms, as a sole agent or in combination with other active ingredients. 

Benzimidazol-2-amines as MIDH1 inhibitors

The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-aryl derivatives of the formula I with progesterone-antagonizing action and to processes for preparation thereof, to use thereof for treatment and/or prophylaxis of disorders and to the use thereof for production of medicaments for treatment and/or prophylaxis of disorders, especially of fibroids of the uterus (myomas, uterine leiomyomas), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause, or for fertility control and emergency contraception.

17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-aryl derivatives, methods for the production thereof and the use thereof for treating diseases

The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-benzylidene derivatives of the formula I, in which Y and X are each as defined in the claims and the description, to a process for preparation thereof and to the use thereof as medicaments.

17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-benzylidene derivatives, methods for the production thereof and use thereof for treating diseases

The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of formula I with progesterone-antagonizing action and methods of production thereof, use thereof for the treatment and/or prevention of diseases and use thereof for producing medicinal products for the treatment and/or prevention of diseases, in particular uterine fibroids (myomata, uterine leiomyomata), endometriosis, heavy menstrual bleeding, meningiomata, hormone-dependent breast cancers and menopause-associated complaints or for fertility control and emergency contraception.

Progesterone receptor antagonists

The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene 11-ethynylphenyl derivatives of the formula I, in which Rand X are each as defined in the claims and the description, and to a process for preparation thereof and to the use thereof as medicaments.

17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-ethynylphenyl derivatives, methods for the production thereof and use thereof for treating diseases

The invention relates to 17-hydroxy-13-methyl-17-pentafluoroethyl-11-acyloxyalkylenephenyldodecahydrocyclopenta[a]phenanthren-3-one derivatives of the formula I with progesterone-antagonizing action and to processes for preparation thereof, to use thereof for treatment and/or prophylaxis of disorders and to the use thereof for production of medicaments for treatment and/or prophylaxis of disorders, especially of fibroids of the uterus (myomas, uterine leiomyomas), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause, or for fertility control and emergency contraception.

17-hydroxy-17-pentafluorethyl-estra-4,9(10)-dien-11-acyloxyalkylene phenyl derivatives, methods for the production thereof and use thereof for treating diseases

The invention relates to 17-hydroxy-17-pentafluoroethylestra-4,9(10)-diene-11-methyleneoxyalkylenearyl derivative of the formula I with progesterone-antagonising action and to processes for preparation thereof, to use thereof for treatment and/or prophylaxis of disorders and to the use thereof for production of medicaments for treatment and/or prophylaxis of disorders, especially of fibroids of the uterus (myomas, uterine leiomyomas), endometriosis, heavy menstrual bleeds, meningiomas, hormone-dependent breast cancers and complaints associated with the menopause, or for fertility control and emergency contraception.

17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-diene-11-methylene oxyalkylene aryl derivatives, process for preparation thereof, and use thereof for treatment of diseases

The invention relates to 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl derivatives of the formula I with a progesterone antagonizing effect and processes for their preparation, their use for the treatment and/or prophylaxis of diseases, and also their use for producing medicaments for the treatment and/or prophylaxis of diseases, in particular of uterus fibroids (myomas, uterine leiomyomas), endometriosis, heavy menstrual bleeding, meningiomas, hormone-dependent breast cancers and troubles associated with the menopause or for monitoring fertility and emergency contraception.

This invention relates to compounds of general formula I in which Rand Rare described in this application, the use of the compounds of general formula I as inhibitors of protein tyrosine kinases for treatment of various diseases as well as the compounds of general formulas II and III as intermediate compounds for the production of compounds of general formula I, wherein X, Rand Rhave the meaning that is described in general formulas II and III.

3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents

Growing community of inventors

Glienicke, Germany

Wolfgang Schwede